Genmab A/SGMAB
Key ratios
Operating cash flow growth
-14.1%TTM
2025
5.3%2024
5.1%2023
84.9%
EPS growth
-36.8%TTM
2025
-12.3%2024
83.0%2023
-21.7%
FCF / Sales
21.0%TTM
2025
30.9%2024
35.2%2023
42.6%
Net margin
19.1%TTM
2025
25.9%2024
36.3%2023
26.4%
ROA
8.1%2025
2024
10.9%2023
10.0%
ROE
17.5%2025
2024
23.1%2023
14.5%
Revenue growth
22.3%TTM
2025
19.2%2024
30.6%2023
11.3%
Recent news
Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in 1L PD-L1+ R/M Head and Neck Cancer
Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Genmab Announces Rinatabart Sesutecan (Rina-S) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Major Shareholder Announcement
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Track GMAB in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer